Melodiol Global Health Limited

ASX:ME1 Stock Report

Market Cap: AU$1.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Melodiol Global Health Management

Management criteria checks 1/4

Melodiol Global Health's CEO is Will Lay, appointed in Jan 2022, has a tenure of 2.75 years. total yearly compensation is A$894.88K, comprised of 46% salary and 54% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth A$70.81. The average tenure of the management team and the board of directors is 4.3 years and 2.8 years respectively.

Key information

Will Lay

Chief executive officer

AU$894.9k

Total compensation

CEO salary percentage46.0%
CEO tenure2.8yrs
CEO ownership0.006%
Management average tenure4.3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01
Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02
Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

May 11
Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

CEO Compensation Analysis

How has Will Lay's remuneration changed compared to Melodiol Global Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023AU$895kAU$412k

-AU$36m

Jun 30 2023n/an/a

-AU$54m

Mar 31 2023n/an/a

-AU$43m

Dec 31 2022AU$408kAU$389k

-AU$22m

Compensation vs Market: Will's total compensation ($USD588.46K) is above average for companies of similar size in the Australian market ($USD299.30K).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Lay

2.8yrs

Tenure

AU$894,875

Compensation

Mr. William Lay, also known as Will, B.Com (Hons.) is CEO & MD of Health House International Limited from 2024. He serves as Group Chief Executive Officer, Managing Director and Director at Melodiol Global...

Leadership Team

NamePositionTenureCompensationOwnership
Boaz Wachtel
Co-Founder & Non-Executive Chairman8.9yrsAU$80.00k0.0015%
A$ 17.2
William Lay
Group CEO2.8yrsAU$894.88k0.0063%
A$ 70.8
Christopher Grundy
Chief Financial Officer6.9yrsAU$628.01k0.00014%
A$ 1.6
Micheline MacKay
Executive Director2.8yrsAU$265.90k0.00046%
A$ 5.2
Gian Trepp
Commercial & Marketing Director5.8yrsno datano data
Mitchel Fleming
Managing Director of Halucenexno datano datano data
Brett Ayers
Managing Director of Impactiveno datano datano data
Winton Willesee
Joint Company Secretary6yrsno datano data
Brian Walker
Strategic Consultant & Chair of Scientific Advisory Committee2.9yrsno datano data

4.3yrs

Average Tenure

Experienced Management: ME1's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Boaz Wachtel
Co-Founder & Non-Executive Chairman8.9yrsAU$80.00k0.0015%
A$ 17.2
William Lay
Group CEO2.8yrsAU$894.88k0.0063%
A$ 70.8
Micheline MacKay
Executive Director2.8yrsAU$265.90k0.00046%
A$ 5.2
Brian Walker
Strategic Consultant & Chair of Scientific Advisory Committee2.9yrsno datano data
Walter Von Wartburg
Member of Scientific Advisory Board5.8yrsno datano data
Bruce Linton
Independent Non-Executive Director2.8yrsAU$82.72k0.0019%
A$ 22.0
Isaac Kobrin
Member of Scientific Advisory Boardno datano datano data
Felix Gutzwiller
Member of Scientific Advisory Board7.6yrsno datano data
Peter Hatfull
Non-Executive Director1.9yrsAU$83.26kno data
Ben Quirin
Non-Executive Director2yrsAU$82.80kno data

2.8yrs

Average Tenure

73.5yo

Average Age

Experienced Board: ME1's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/31 19:41
End of Day Share Price 2024/08/28 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Melodiol Global Health Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution